Try
HUTCHMED (China) Ltd
HCMUnited States
24 filed reports · 640 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
24 reports · Dec 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 1,425 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Interim · 6-KSEC EDGAR | 14 | 3,199 | Jun 2017 to Jun 2026 |
| Annual · 20-FSEC EDGAR | 10 | 5,403 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 6-K | Jun 30, 2026 | Jul 30, 2026 | 98 | Open |
| FY2026 Q2 | 6-K | Jun 30, 2026 | Jul 30, 2026 | 395 | Open |
| FY2025 | 20-F | Dec 31, 2025 | Mar 5, 2026 | 868 | Open |
| FY2025 Q2 | 6-K | Jun 30, 2025 | Aug 7, 2025 | 209 | Open |
| FY2025 Q2 | 6-K | Jun 30, 2025 | Aug 7, 2025 | 4 | Open |
| FY2024 | 20-F | Dec 31, 2024 | Mar 19, 2025 | 449 | Open |
| FY2024 Q2 | 6-K | Jun 30, 2024 | Jul 31, 2024 | 191 | Open |
| FY2023 | 20-F | Dec 31, 2023 | Feb 28, 2024 | 498 | Open |
| FY2023 Q2 | 6-K | Jun 30, 2023 | Jul 31, 2023 | 186 | Open |
| FY2022 | 20-F | Dec 31, 2022 | Feb 28, 2023 | 441 | Open |
| FY2022 Q2 | 6-K | Jun 30, 2022 | Aug 1, 2022 | 164 | Open |
| FY2021 | 20-F | Dec 31, 2021 | Mar 3, 2022 | 518 | Open |
Financial data
640 concepts · 8,602 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial583 concepts · 6,549 facts · Dec 2014 to Jun 2026
- Debt instrument unused borrowing capacity amount45 · Dec 2015 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest39 · Dec 2014 to Jun 2026
- Allowance for doubtful accounts receivable38 · Dec 2014 to Dec 2025
- Cash and cash equivalents at carrying value37 · Dec 2014 to Jun 2026
- Goodwill (US GAAP)36 · Dec 2014 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents35 · Dec 2015 to Jun 2026
- Common stock par or stated value per share35 · Dec 2015 to Jun 2026
- Debt weighted average interest rate35 · Dec 2015 to Jun 2026
- Property plant and equipment net35 · Dec 2015 to Jun 2026
- Accounts payable current34 · Dec 2015 to Jun 2026
- Accounts receivable net current34 · Dec 2015 to Jun 2026
- Accrued administrative and other general expenses34 · Dec 2015 to Jun 2026
- Accrued research and development expenses34 · Dec 2015 to Jun 2026
- Accumulated other comprehensive income loss net of tax34 · Dec 2015 to Jun 2026
- Additional paid in capital common stock34 · Dec 2015 to Jun 2026
- Assets34 · Dec 2015 to Jun 2026
- Assets current34 · Dec 2015 to Jun 2026
- Common stock shares authorized34 · Dec 2015 to Jun 2026
- Common stock shares issued34 · Dec 2015 to Jun 2026
- Common stock value34 · Dec 2015 to Jun 2026
- Deferred government grants34 · Dec 2015 to Jun 2026
- Employee related liabilities current34 · Dec 2015 to Jun 2026
- Equity method investments34 · Dec 2015 to Jun 2026
- Inventory finished goods net of reserves34 · Dec 2015 to Jun 2026
Segment35 concepts · 1,624 facts · Dec 2014 to Jun 2026
- Revenue241 · Dec 2014 to Dec 2025
- Revenue (excluding assessed tax)139 · Jun 2017 to Jun 2026
- Net income loss122 · Dec 2015 to Dec 2025
- Income tax expense benefit117 · Dec 2014 to Dec 2025
- Depreciation depletion and amortization116 · Dec 2014 to Dec 2025
- Investment income interest111 · Dec 2014 to Dec 2025
- Payments to acquire productive assets97 · Dec 2014 to Dec 2022
- Reportable segment96 · Dec 2015 to Dec 2021
- Income loss from equity method investments87 · Dec 2014 to Dec 2025
- Property, Plant & Equipment, Net52 · Dec 2016 to Jun 2026
- Total Assets52 · Dec 2016 to Jun 2026
- Adjusted (LBIT)/EBIT51 · Dec 2014 to Jun 2019
- Depreciation & Amortization30 · Jun 2016 to Jun 2026
- Income Tax Expense (Benefit)30 · Jun 2016 to Jun 2026
- Net Income30 · Jun 2016 to Jun 2026
- Interest expense (US GAAP)25 · Dec 2014 to Dec 2023
- Segment expenditure addition to long lived assets24 · Dec 2021 to Dec 2025
- Goodwill22 · Dec 2016 to Jun 2026
- Intangible Assets (excluding Goodwill)19 · Dec 2016 to Dec 2025
- Capital Expenditures17 · Jun 2016 to Jun 2023
- Interest Expense17 · Jun 2016 to Jun 2026
- General and administrative expense (US GAAP)16 · Dec 2022 to Dec 2025
- Segment reporting other item amount16 · Dec 2022 to Dec 2025
- Cost of Goods and Services Sold12 · Jun 2024 to Jun 2026
Product6 concepts · 225 facts · Dec 2016 to Jun 2026
- Revenue (excluding assessed tax)98 · Jun 2017 to Jun 2026
- Revenue89 · Dec 2016 to Dec 2025
- Accounts Payable17 · Mar 2019 to Jun 2026
- Accounts Receivable, Net17 · Mar 2019 to Jun 2026
- Inventory2 · Mar 2019 to Jun 2019
- Milestone payment received2 · Dec 2018
Geography16 concepts · 204 facts · Dec 2014 to Jun 2026
- Current income tax expense benefit50 · Dec 2014 to Dec 2024
- Effective income tax rate reconciliation at federal statutory income tax rate35 · Dec 2014 to Dec 2024
- PRC15 · Dec 2014 to Dec 2024
- HBYS and SHPL14 · Dec 2015 to Dec 2024
- Property, Plant & Equipment, Net14 · Dec 2023 to Jun 2026
- Total Assets14 · Dec 2023 to Jun 2026
- Hong Kong12 · Dec 2021 to Dec 2024
- Revenue (excluding assessed tax)12 · Jun 2024 to Jun 2026
- Income tax reconciliation tax credits research10 · Dec 2021 to Dec 2025
- Revenue7 · Dec 2022 to Dec 2025
- Effective income tax rate reconciliation state and local income taxes6 · Dec 2018 to Dec 2020
- Goodwill4 · Dec 2024 to Jun 2026
- Number of subsidiaries incorporated in the British Virgin Islands subject to HK profits tax4 · Sep 2018 to Sep 2019
- Deferred income tax expense benefit3 · Dec 2014 to Dec 2016
- Intangible Assets (excluding Goodwill)2 · Jun 2025 to Dec 2025
- U.S. withholding tax (as a percent)2 · Dec 2023 to Dec 2024
Segments
2,053 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments8 members · 862 facts
- Oncology or immunology segment165 · Dec 2019 to Jun 2026
- Commercial Platform145 · Dec 2016 to Dec 2019
- Other ventures segment142 · Dec 2019 to Jun 2026
- Oncology Or Immunology130 · Dec 2018 to Dec 2025
- Commercial platform117 · Jun 2016 to Jun 2020
- Other Ventures111 · Dec 2018 to Dec 2025
- Innovation Platform32 · Dec 2016 to Dec 2019
- Innovation platform20 · Dec 2017 to Jun 2020
Subsegments6 members · 762 facts
- Consumer Health270 · Dec 2014 to Dec 2019
- Research And Development Subsegment158 · Dec 2018 to Dec 2025
- Prescription Drugs141 · Dec 2014 to Dec 2019
- Drug Research And Development136 · Dec 2014 to Dec 2019
- Marketed Products Subsegment56 · Dec 2018 to Dec 2025
- Reportable Subsegments1 · Dec 2016
Product or servicesrt:ProductOrServiceAxis32 members · 217 facts
- Seroquel36 · Mar 2019 to Jun 2026
- Goods Distribution13 · Dec 2017 to Dec 2025
- Goods distribution13 · Jun 2018 to Jun 2026
- Services13 · Dec 2016 to Dec 2019
- Collaboration research and development10 · Jun 2020 to Jun 2026
- Marketed products10 · Jun 2020 to Jun 2026
- Other collaboration royalties revenue10 · Jun 2020 to Jun 2026
- Commercialization services9 · Jun 2021 to Jun 2026
- Collaboration Research And Development8 · Dec 2018 to Dec 2025
- Commercialization Services8 · Dec 2018 to Dec 2025
- Marketed Products8 · Dec 2018 to Dec 2025
- Other Collaboration Royalties Revenue8 · Dec 2018 to Dec 2025
- Services7 · Mar 2018 to Jun 2020
- Research And Development Services7 · Dec 2018 to Dec 2024
- License and collaborations manufacturing supply6 · Jun 2024 to Jun 2026
- Other collaboration licensing revenue6 · Jun 2022 to Jun 2026
- Research and development services6 · Jun 2020 to Jun 2024
- Other Collaboration Licensing Revenue6 · Dec 2018 to Dec 2025
- Goods5 · Dec 2016 to Mar 2019
- Goods3 · Mar 2018 to Mar 2019
- Royalties3 · Jun 2019 to Jun 2020
- License And Collaborations Manufacturing Supply3 · Dec 2023 to Dec 2025
- Licenses3 · Dec 2018
- Royalty3 · Dec 2018 to Dec 2019
- Goods Innovative Medicines2 · Dec 2018 to Dec 2019
- Goods distribution and other products2 · Jun 2021 to Jun 2022
- Goods innovative medicines2 · Jun 2019 to Jun 2020
- Goods manufacturing2 · Jun 2019 to Sep 2019
- Milestones2 · Dec 2016 to Dec 2017
- Goods Manufacturing1 · Sep 2019
- Royalties1 · Sep 2019
- Royalty1 · Mar 2019
Statement geographicalsrt:StatementGeographicalAxis13 members · 178 facts
- CN54 · Dec 2016 to Dec 2025
- HK33 · Dec 2016 to Dec 2024
- Cn26 · Dec 2023 to Jun 2026
- United states and others20 · Dec 2023 to Jun 2026
- US12 · Sep 2018 to Dec 2025
- United States And Others10 · Dec 2018 to Dec 2025
- NJ5 · Dec 2021 to Dec 2025
- GB4 · Dec 2021 to Dec 2024
- VG4 · Sep 2018 to Sep 2019
- United States New Jersey3 · Dec 2018 to Dec 2020
- United States New York3 · Dec 2018 to Dec 2020
- European Countries2 · Dec 2019 to Dec 2020
- FI2 · Dec 2018 to Dec 2019
Statement geographicalus-gaap:StatementGeographicalAxis2 members · 26 facts
- CN18 · Dec 2014 to Dec 2017
- HK8 · Dec 2014 to Dec 2017
Product or serviceus-gaap:ProductOrServiceAxis4 members · 8 facts
- Revenue from license and collaboration agreements third parties2 · Jun 2017 to Jun 2018
- Revenue from research and development services related parties2 · Jun 2017 to Jun 2018
- Sales related parties2 · Jun 2017 to Jun 2018
- Sales third parties2 · Jun 2017 to Jun 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.